Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033
T: +91 40 23635000,
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

November 13, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Symbol: VIYASH

Dear Sir/ Madam,

Subject: Press Release for Q2 FY27

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release on Q2 FY27 Financial Results.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully,
For **Viyash Scientific Limited**
(Formerly known as Sequent Scientific Limited)

YOSHITA SUSMIT VORA
Digitally signed by YOSHITA SUSMIT VORA
Date: 2026.11.13 18:32:34 +05'30'

Yoshita Vora
Company Secretary & Compliance Officer

Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)
Registered Office: Plot No. 290, Srivaili's Corporate, Road No. 6, Madhapur, Hyderabad - 500081, Telangana State, India

T: +91 40 23635000, E:info@viyash.com E: investorrelations@viyash.com
Website: www.viyash.com CIN: L99999TS1985PLC196357

Hyderabad, November 13, 2026: Viyash Scientific Limited (formerly SeQuent Scientific Limited) an integrated pharmaceutical company with businesses across Formulations, APIs and CDMO services for Human and Animal Health, today announced its financial results for the quarter and half year ended September 30, 2026.

Viyash Scientific H1 FY27: Revenue up 17.8% to ₹ 19,343 Mn; H1 PAT up 49% to ₹ 1,639 Mn

REVENUE | Q2 FY27	EBITDA* | Q2 FY27	PAT | Q2 FY27	Adjusted PAT** | Q2 FY27	NET DEBT / EBITDA*
₹ 9,879 Mn	₹ 2,077 Mn	₹ 847 Mn	₹ 1,110 Mn	0.0x
↑ 16.2% YoY	↑ 10.3% YoY | 21.0% margin	↑ 16.1% YoY		↓ from 0.7x last year

** EBITDA before ESOP costs*
***Assuming a normalised annual ESOP cost of INR 25 Cr*

Commenting on the Company's performance, **Dr Hari Babu Bodepudi, Managing Director and Group CEO** stated that

*"Viyash Scientific has delivered yet another stellar quarter with H1 revenue up 17.8% and H1 profit after tax (PAT) at INR 164 Cr, up ~50% from last year. H1 adjusted PAT with normalized ESOP cost is INR 204 Cr**. The completion of acquisition of BioForLife in Italy strengthens our companion animal platform. We are also investing in new oncology capabilities, in-house companion animal manufacturing facility and expanding our API capacity to meet customer demand.*

Our focus remains on disciplined execution, R&D-led growth and sustainable value creation for customers and stakeholders."

Dr Hari Babu Bodepudi, Managing Director and Group CEO

*** Assuming a normalised annual ESOP cost of INR 25 Cr.*

Consolidated Financial Highlights

₹ in millions

Particulars	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ	H1 FY27	H1 FY26	YoY
Revenue from operations	**9,879**	**8,503**	**+16.2%**	**9,464**	**+4.4%**	**19,343**	**16,419**	**+17.8%**
EBITDA*	**2,077**	**1,883**	**+10.3%**	**2,047**	**+1.5%**	**4,124**	**3,176**	**+29.9%**
EBITDA %*	*21.0%*	*22.1%*		*21.6%*		*21.3%*	*19.3%*	
Profit after tax (PAT)	**847**	**729**	**+16.1%**	**793**	**+6.8%**	**1,639**	**1,098**	**+49.4%**

** EBITDA before ESOP costs*

Earnings call with investors

The Company will hold an earnings call at **11:00 AM IST on November 14, 2026**, where management will discuss the Company's performance and take questions from participants.

Dial-in (please dial 10 minutes before the start time): **+91 22 6280 1263 or +91 22 7115 8213**

About Viyash Scientific Limited

Viyash Scientific Limited (formerly SeQuent Scientific Limited), headquartered in Hyderabad, India, is an integrated pharmaceutical platform across animal and human health, backed by science and IP, and is among the top-25 animal health companies globally. Its portfolio spans 110+ APIs, 30+ human health and 140+ animal health formulations, serving customers in 150+ countries.

The Company operates 16 manufacturing facilities and R&D, manufacturing and distribution operations across India, Spain, Brazil, Turkey, and the USA with approvals from international regulators including USFDA, EU GMP, WHO and TGA. It has 3,300+ employees, 335+ scientists, 190+ patents filed and 1,000+ registrations.

For further information

Yoshita Vora
Company Secretary
+91 22 4111 4777
investorrelations@viyash.com

Abhishek Singhal
Investor Relations Consultant
abhishek@arunya.co.in

Registered office: Plot No. 290, Srivaili's Corporate, Road No. 6, Madhapur, Hyderabad - 500081, Telangana State, India | www.viyash.com | CIN: L99999TS1985PLC196357 | BSE: 512529 | NSE: VIYASH | ISIN: INE807F01027

Safe harbour: Certain statements in this document that are not historical facts are forward-looking statements. Such statements are subject to risks and uncertainties, including government actions, local, political or economic developments and technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the forward-looking statements. Viyash Scientific Limited will not be responsible in any way for any action taken based on such statements and undertakes no obligation to publicly update them to reflect subsequent events or circumstances.